Table 5 |
|||||||||
| Multivariate analysis | |||||||||
| PSA Progression-Free Survival | |||||||||
| Model 1 | Model 2 | Model 3 | |||||||
| HR | (95%CI) | p= | HR | (95%CI) | p= | HR | (95%CI) | p= | |
| PSA,ng/ml | |||||||||
| ≤10ng/ml | 1.0 | 1.0 | 1.0 | ||||||
| >10ng/ml | 1.39 | (0.66-2.96) | 0.4 | 1.25 | (0.58-2.68) | 0.6 | 1.29 | (0.60-2.78) | 0.5 |
| Extra-prostatic extension | |||||||||
| Yes | 1.0 | 1.0 | 1.0 | ||||||
| No | 3.30 | (1.29-8.47) | 0.01 | 3.21 | (1.27-8.07) | 0.01 | 3.20 | (1.27-8.09) | 0.01 |
| Pelvic nodes involved | |||||||||
| N0 | 1.0 | 1.0 | 1.0 | ||||||
| N+ | 1.55 | (0.68-3.55) | 0.3 | 1.37 | (0.60-3.14) | 0.4 | 1.39 | (0.61-3.18) | 0.4 |
| Surgical margins involved | |||||||||
| No | 1.0 | 1.0 | 1.0 | ||||||
| Yes | 0.75 | (0.31-1.81) | 0.5 | 0.72 | (0.31-1.67) | 0.4 | 0.68 | (0.29-1.62) | 0.4 |
| Seminal vesicles involved | |||||||||
| No | 1.0 | 1.0 | 1.0 | ||||||
| Yes | 0.77 | (0.35-1.70) | 0.5 | 0.64 | (0.28-1.44) | 0.3 | 0.64 | (0.28-1.43) | 0.3 |
| Gleason score | |||||||||
| <7 | 1.0 | ||||||||
| ≥7 | 2.02 | (0.90-4.54) | 0.09 | ||||||
| Gleason score | |||||||||
| ≤7 | 1.0 | ||||||||
| >7 | 3.29 | (1.62-6.65) | 0.001 | ||||||
| Gleason score | |||||||||
| <7 | 1.0 | 0.03 | |||||||
| =7 | 1.32 | (0.54-3.26) | 0.5 | ||||||
| >7 | 3.89 | (1.58-9.54) | 0.003 | ||||||
| Stromal -Epithelial IRS Score | |||||||||
| =12/≤2 | 1.0 | 0.08 | 1.0 | 0.2 | 1.0 | 0.2 | |||
| <12/≤2 | 0.47 | (0.19-1.17) | 0.1 | 0.52 | (0.20-1.33) | 0.2 | 0.53 | (0.21-1.37) | 0.2 |
| =12/>2 | 0.14 | (0.01-1.33) | 0.09 | 0.19 | (0.02-1.89) | 0.2 | 0.19 | (0.02-1.89) | 0.2 |
| <12/>2 | 0.09 | (0.01-0.77) | 0.03 | 0.11 | (0.01-1.10) | 0.06 | 0.12 | (0.01-1.11) | 0.06 |
Abbreviations:HR,Hazard Ratio;CI ,Confidence Interval; PSA,Prostate-specific antigen;IRS, Immuno-reactive score.
Nuzzo et al. BMC Cancer 2012 12:625 doi:10.1186/1471-2407-12-625
